Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therap
Exhibitor: TFBS BIOSCIENCE, INC.
Date: 2025-06-11
Booth No.: M827
Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therapy for Rare Disease
Taipei, Taiwan–11th June 2025— Dr. Paul Wuh-Liang Hwu, MD, PhD, Professor Emeritus of Pediatrics and Medical Genetics at National Taiwan University, and Distinguished Research Fellow at the Center for Precision Medicine, China Medical University Hospital, has recently launched a new gene therapy development project targeting Sialidosis, a rare genetic disorder. The research utilizes adeno-associated virus serotype 9 (AAV9) as a vector to deliver the sialidase gene into the human body, offering a potential effective treatment for patients. TFBS Bioscience, serving as the manufacturing partner, will provide a one-stop service for AAV9 vector process development, GMP-grade clinical trial material manufacturing, and quality and safety testing to support Phase I/II clinical trials.
Sialidosis is a rare lysosomal storage disorder caused by a deficiency in sialidase, which disrupts the metabolism of sialic acid, leading to an accumulation of undegraded sialylated oligosaccharides in cells. This buildup affects the central nervous system, skeletal system, and reticuloendothelial system. Symptoms include gait disturbances, vision loss, myoclonus, ataxia, leg tremors, and seizures. Myoclonus worsens over time, eventually impairing a patient’s ability to sit, stand, or walk without assistance, often requiring the use of a wheelchair. Currently, there is no cure for Sialidosis; patients rely mainly on supportive therapies to manage symptoms. If clinical trials prove this AAV9-based gene therapy to be safe and effective, it could become a new therapeutic option for patients.
Professor Hwu is a leading figure in gene therapy in Taiwan. During his tenure at the Department of Pediatrics and Institute of Genetics at National Taiwan University Hospital (NTUH), he successfully developed the world’s first AAV-based gene therapy for Aromatic L-amino Acid Decarboxylase (AADC) deficiency. It was the first gene therapy in Taiwan to be licensed to a global pharmaceutical company, receiving marketing authorization from the EU in 2022 and the US in 2024. His accomplishment in gene therapy has inspired the scientists domestically and internationally. Following his retirement from NTU, Professor Hwu has joined China Medical University Hospital in Taichung, Taiwan to continue his pursuit in gene therapy development for various rare genetic diseases, including Sialidosis.
TFBS Bioscience began as a biosafety testing organization and has since become Taiwan’s first—and only—GMP-certified viral vector CDMO. It provides comprehensive one-stop services for biopharmaceuticals and cell and gene therapy products, covering key stepsfrom method development to manufacturing and quality control.
Having already brought real benefits to patients through his pioneering AADC gene therapy, Professor Hwu is now leveraging his experience to tackle Sialidosis. With the support of the NTUH Center for Frontier Medicine, his team has successfully demonstrated therapeutic efficacy in a mouse model. Forward-looking planning is now underway with the goal of accelerating the path to clinical application and bringing hope to patients suffering from this rare disorder.
TFBS Bioscience, selected as the manufacturing partner, demonstrates Taiwan’s robust capabilities in gene therapy development and manufacturing. This collaboration offers new hope to Sialidosis patients worldwide, proving that Taiwan can play a critical role in the advancement of gene therapy from research to product realization.
More Exhibitor's Press Release
- Honya Medical Strengthens Local Presence and Expands Toward Global Clinical Excellence HONYA MEDICAL CO., LTD. / 2025-07-30
- Honya’s MiSaver: A New Frontier in Treating Heart Damage After Heart Attacks HONYA MEDICAL CO., LTD. / 2025-07-30
- Link-Best debuted at BIO Asia Exhibition. Products attracted attention and Ignited Spark. LINK-BEST BIOSCIENCE CO., LTD. / 2025-07-30
- GoldenBiotech-Advancing First-line treatment of Meta. PanCa GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GlobalBio: 國鼎生技-開發Antroquinonol 造福抗癌研究治療 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Technology Platform TFBS BIOSCIENCE, INC. / 2025-07-25
- Visit Us at BIO Asia–Taiwan 2025! July 24 – July 27 GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-25
- GBC CellBio™ a2000 has been recognized with a 2025 Edison Award. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- GBC AI Biotech Building Officially Commissioned. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-24
- Ecotek Engineering Corp.: Your Integrated Partner for Biopharma Facility and Process Equipment Solut MAJOR SCIENCE CO.,LTD / 2025-07-24
- About major science - Create life sciences research instruments through quality and innovation MAJOR SCIENCE CO.,LTD / 2025-07-24
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-24
- MarkerX Unveils MyeloTrak™ at BIO Asia, Redefining Multiple Myeloma Management with Non-invasive, Pr MARKER X CO., LTD. / 2025-07-23
- CancerFree Biotech Selected for OIST Startup Accelerator Program CANCERFREE BIOTECH LTD. / 2025-07-23
- AI Sparks a New Wave in Cancer Research: How a Taiwanese Startup Is Breaking Lab Bottlenecks and Ad CANCERFREE BIOTECH LTD. / 2025-07-23
- Transin Biomedical showcases the innovative strength of smart medical devices TRANSIN BIOMEDICAL CO., LTD. / 2025-07-23
- TaiMed Biologics Hosts Interactive Activities at BIO Asia 2025 to Promote HIV Awareness TAIMED BIOLOGICS INC. / 2025-07-22
- A Pioneer for Over Two Decades, Cell-Bio Biotechnology to Showcase Comprehensive Solutions at BioAsi CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-22